Key result
Drug cessation with or without corticosteroids most effectively resolves 5-ASA-induced pericarditis in IBD.
Why the study?
Pericarditis is a rare cardiovascular manifestation in IBD with unclear pathogenesis and management, including whether it is an extraintestinal manifestation or drug-induced complication.
What is the pathogenesis and optimal management of pericarditis in patients with inflammatory bowel disease?
Systematic Review (n=36)
What is the pathogenesis and optimal management of pericarditis in patients with inflammatory bowel disease?
Pericarditis in IBD is frequently a drug-induced complication from 5-ASA derivatives, which can be effectively managed by discontinuing the offending agent or initiating corticosteroids.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to prioritize 5-ASA cessation in IBD-associated pericarditis; extends case reports with systematic synthesis of drug-induced etiology.
Inflammatory bowel disease (IBD) is a chronic condition of the bowel that can be further categorized into ulcerative colitis and Crohn's disease. Rarely, this condition can be associated with pericarditis, which can be an extraintestinal manifestation of the disease or drug-induced. This review aims to determine the pathogenesis and management of pericarditis in IBD. In this review, the goal is to elucidate the pathogenesis of pericarditis in IBD and determine if pericarditis is an extraintestinal manifestation of IBD or a complication of current drug therapy used to manage IBD. Additionally, this review intends to explain the first-line management of pericarditis in IBD and explore the role of biologicals in attenuating pericarditis. An electronic search was conducted to identify relevant reports of pericarditis in IBD, and a quality assessment was conducted to identify high-quality articles according to the inclusion criteria. Full-text articles from inception to November 2020 were included, while non-English articles, gray literature, and animal studies were excluded. The majority of studies suggest that pericarditis arises as a complication of drug therapy by 5-aminosalicylic acid derivatives such as sulfasalazine, mesalamine, and balsalazide, and it occurs due to IgE-mediated allergic reactions, direct cardiac toxicity, cell-mediated hypersensitivity reactions, and humoral antibody response to therapy. Drug cessation or the initiation of a corticosteroid regimen seems to be the most effective means of managing pericarditis in IBD due to drug therapy or an extraintestinal manifestation.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2021) conducted a systematic review in Pericarditis in Inflammatory Bowel Disease (IBD) (n=36). 5-aminosalicylic acid (5-ASA) derivatives and drug cessation was evaluated on Resolution of pericarditis. Pericarditis in inflammatory bowel disease primarily arises as a complication of 5-aminosalicylic acid derivative therapy and is most effectively managed by drug cessation with or without corticosteroids.
Synapse has enriched 10 related papers. Consider them for comparative context: